Cargando…

Changes of N6-methyladenosine modulators promote breast cancer progression

BACKGROUND: Breast cancer (BC) displays striking genetic, epigenetic and phenotypic diversity. N(6)-methyladenosine (m6A) in mRNA has emerged as a crucial epitranscriptomic modification that controls cancer self-renewal and cell fate. However, the key enzymes of m6A expression and function in human...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Lianpin, Wu, Dengying, Ning, Jinfeng, Liu, Wei, Zhang, Donghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451293/
https://www.ncbi.nlm.nih.gov/pubmed/30953473
http://dx.doi.org/10.1186/s12885-019-5538-z
_version_ 1783409170309971968
author Wu, Lianpin
Wu, Dengying
Ning, Jinfeng
Liu, Wei
Zhang, Donghong
author_facet Wu, Lianpin
Wu, Dengying
Ning, Jinfeng
Liu, Wei
Zhang, Donghong
author_sort Wu, Lianpin
collection PubMed
description BACKGROUND: Breast cancer (BC) displays striking genetic, epigenetic and phenotypic diversity. N(6)-methyladenosine (m6A) in mRNA has emerged as a crucial epitranscriptomic modification that controls cancer self-renewal and cell fate. However, the key enzymes of m6A expression and function in human breast carcinogenesis remain unclear. METHODS: The expression of m6A methylases (METTL3, METTL14 and WTAP) and demethylases (FTO and ALKBH5) were analyzed by using ONCOMINE and The Cancer Genome Atlas databases and in 36 pairs of BC and adjacent non-cancerous tissue. The level of m6A in BC patients was detected by ELISA, and the function of m6A was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, colony formation assay and transwell assay. The database of bc-GenExMiner v4.0, Kaplan-Meier Plotter and cBioPortal were queried for correlation, mutation and prognosis analysis of BC. RESULTS: The m6A methylases and demethylases were dysregulated in several major malignant tumors. Specifically, the expression of all m6A methylases was reduced in BC as compared with normal controls, but the demethylase ALKBH5 was induced in ONCOMINE databases and confirmed in clinical patients. METTL14 expression was positively correlated with METTL3 expression, and both showed high expression in normal breast-like and luminal-A and -B BC. Functionally, reducing m6A expression by overexpressing METTL14 and/or knockdown of ALKBH5 could inhibit breast cell viability, colony formation and cell migration. Furthermore, Kaplan-Meier, meta-analysis and univariate Cox assay showed that the expression of m6A members including METTL3, METTL14, WTAP and FTO but not their gene mutation and amplification, was tightly associated with cancer progression and poor survival. CONCLUSIONS: Changes of m6A modulators reduced m6A may promote tumorigenesis and predict poor prognosis in BC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5538-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6451293
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64512932019-04-17 Changes of N6-methyladenosine modulators promote breast cancer progression Wu, Lianpin Wu, Dengying Ning, Jinfeng Liu, Wei Zhang, Donghong BMC Cancer Research Article BACKGROUND: Breast cancer (BC) displays striking genetic, epigenetic and phenotypic diversity. N(6)-methyladenosine (m6A) in mRNA has emerged as a crucial epitranscriptomic modification that controls cancer self-renewal and cell fate. However, the key enzymes of m6A expression and function in human breast carcinogenesis remain unclear. METHODS: The expression of m6A methylases (METTL3, METTL14 and WTAP) and demethylases (FTO and ALKBH5) were analyzed by using ONCOMINE and The Cancer Genome Atlas databases and in 36 pairs of BC and adjacent non-cancerous tissue. The level of m6A in BC patients was detected by ELISA, and the function of m6A was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, colony formation assay and transwell assay. The database of bc-GenExMiner v4.0, Kaplan-Meier Plotter and cBioPortal were queried for correlation, mutation and prognosis analysis of BC. RESULTS: The m6A methylases and demethylases were dysregulated in several major malignant tumors. Specifically, the expression of all m6A methylases was reduced in BC as compared with normal controls, but the demethylase ALKBH5 was induced in ONCOMINE databases and confirmed in clinical patients. METTL14 expression was positively correlated with METTL3 expression, and both showed high expression in normal breast-like and luminal-A and -B BC. Functionally, reducing m6A expression by overexpressing METTL14 and/or knockdown of ALKBH5 could inhibit breast cell viability, colony formation and cell migration. Furthermore, Kaplan-Meier, meta-analysis and univariate Cox assay showed that the expression of m6A members including METTL3, METTL14, WTAP and FTO but not their gene mutation and amplification, was tightly associated with cancer progression and poor survival. CONCLUSIONS: Changes of m6A modulators reduced m6A may promote tumorigenesis and predict poor prognosis in BC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5538-z) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-05 /pmc/articles/PMC6451293/ /pubmed/30953473 http://dx.doi.org/10.1186/s12885-019-5538-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wu, Lianpin
Wu, Dengying
Ning, Jinfeng
Liu, Wei
Zhang, Donghong
Changes of N6-methyladenosine modulators promote breast cancer progression
title Changes of N6-methyladenosine modulators promote breast cancer progression
title_full Changes of N6-methyladenosine modulators promote breast cancer progression
title_fullStr Changes of N6-methyladenosine modulators promote breast cancer progression
title_full_unstemmed Changes of N6-methyladenosine modulators promote breast cancer progression
title_short Changes of N6-methyladenosine modulators promote breast cancer progression
title_sort changes of n6-methyladenosine modulators promote breast cancer progression
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451293/
https://www.ncbi.nlm.nih.gov/pubmed/30953473
http://dx.doi.org/10.1186/s12885-019-5538-z
work_keys_str_mv AT wulianpin changesofn6methyladenosinemodulatorspromotebreastcancerprogression
AT wudengying changesofn6methyladenosinemodulatorspromotebreastcancerprogression
AT ningjinfeng changesofn6methyladenosinemodulatorspromotebreastcancerprogression
AT liuwei changesofn6methyladenosinemodulatorspromotebreastcancerprogression
AT zhangdonghong changesofn6methyladenosinemodulatorspromotebreastcancerprogression